Replies to post #27190 on Mymetics Corp (MYMX)

[Work Harder]

A clinical study of MYM-V101

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 06 May 2019

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=153386495

28 May 2022 No recent reports of development identified for phase-I development in HIV-1-infections(Prevention) in Belgium (IM, Injection)

https://adisinsight.springer.com/drugs/800021858

Where did MYM-201 go ?

https://adisinsight.springer.com/search

Year 4 or now 5 @ the NIH via all over the world, Texas & Louisiana being the main players or more like hiders in partner

LOL

[Work Harder]

Denise is a molecular immunologist. Her research focuses on developing novel immunotherapeutics and immunodiagnostics for complex pathogens that cause chronic diseases, using malaria as a model. Much of her career has focused on malaria immunology and vaccine development.

She was awarded a National Academy of Sciences Postdoctoral Fellowship to work at the United States Naval Medical Research Center with Stephen Hoffman on malaria vaccine development. After appointments as Director of Basic and Preclinical Research & Development and then Scientific Director of the US Navy Malaria Program, she returned to Australia in 2007.

She has strong expertise in the process of vaccine development, spanning the complete vaccine development pipeline from discovery to clinical testing, including regulatory aspects and IND applications.

https://research.jcu.edu.au/portfolio/denise.doolan/

Hail Oxford

LOL